Published on 2 Jan 2024 on Benzinga
Shares of Longboard Pharmaceuticals, Inc. LBPH rose sharply during Tuesday’s session after the company released topline data from the PACIFIC Phase 1b/2a study evaluating bexicaserin (LP352) for seizures associated with a broad range of Developmental and Epileptic Encephalopathies (DEEs).
Longboard Pharmaceuticals shares jumped 199.7% to $18.07 on Tuesday.